Specialists have reported new data on the real-world use of calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapies, showing that reductions in headache frequency are achieved that are similar to those seen in clinical trials.
Specialists have reported new data on the real-world use of calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapies, showing that reductions in headache frequency are achieved that are similar to those seen in clinical trials.